Imagine using a key to open a door, but half the keys sold in stores are actually broken and don't fit. In science, 'antibodies' are those keys used to find diseases, but many current ones are unreliable. This project builds a digital library of synthetic, high-precision 'keys' that are guaranteed to work every time.
Half of the commercial antibodies used in research and diagnostics are non-functional, leading to massive financial waste and unreproducible scientific results.
A platform for synthetic protein design including the ATLIGATOR modelling tool and ParaMAX randomization, resulting in a library of amino acid-binding motifs.
If you are a diagnostic kit manufacturer dealing with unreliable test results due to poor antibody specificity — this project developed synthetic alternatives that replace animal-derived reagents. This ensures higher accuracy in disease detection and reduces the risk of false results.
If you are a reagent supplier dealing with a market where 50% of commercial antibodies are non-functional — this project developed a platform to create high-performing synthetic alternatives. This allows you to offer guaranteed performance and capture a share of the $3.7 billion annual market.
If you are a drug discovery lab dealing with wasted salaries and failed experiments due to poor reagent quality — this project developed a modular protein design system. This eliminates the €0.7 billion annual wastage in the EU caused by non-functional antibodies.
Non-functional antibodies result in an annual wastage of approximately €0.7 billion in the EU alone, excluding the cost of wasted salaries and time.
The project is moving from TRL3 to TRL6, creating a suite of dArmRPs and prototypes for four commercially-relevant targets to reach investment readiness.
Based on available project data, the project is developing a foundational platform technology and seeking an investment of ~€20 M upon completion.
The project runs from 2022-06-01 to 2025-05-31, aiming to reach TRL6 by the end of the period.
The synthetic alternatives are designed to replace low-quality, animal-derived monoclonal antibodies (mAbs) used to detect biomolecules in research and diagnostics.
The consortium consists of 3 university partners from Germany, Switzerland, and the UK. There is a 0% industry ratio, indicating the project is currently driven by academic expertise in biochemistry and computational design rather than commercial partners, which is consistent with its goal of moving from TRL3 to TRL6 for future investment.
Contact Universitat Bayreuth regarding the PRe-ART-2T platform
Contact us to connect with the PRe-ART-2T researchers for licensing opportunities.
